Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Sees Reimbursement Advantage For PCSK9 Launch

Executive Summary

Administration under the medical benefit/Medicare Part B could mean easier reimbursement. The company outlined early plans for the launch of inclisiran after announcing it will buy The Medicines Company for $9.7bn.

You may also be interested in...



Alnylam Secures $2bn Financing From Blackstone By Monetizing Inclisiran Royalties

Alnylam successfully completed a multi-pronged financing deal with the investment firm, which it will use to fund the development of more RNAi drugs.

Novartis Likes US ‘Buy And Bill’ Market For PCSK9 Drug, But Price Will Be Key

Inclisiran's price relative to existing PCSK9 drugs will be key determinant in payer acceptance. Novartis says pricing will be within cost effectiveness range estimated by ICER.

Esperion Aiming For 50% Commercial Coverage For Nexletol

The company hopes to sidestep payer restrictions and patient abandonment by launching the cholesterol-lowering medicine at a palatable price point in line with where branded statins were before patent expiry.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

OM013057

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel